Go Deep
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,424 | 8.9 | 2.61 | 0.06 | 1,910.52 |
| Oct 2026 | 21,505 | 8.7 | 2.56 | 0.06 | 1,858.32 |
| Oct 2026 | 21,713 | 8.3 | 2.46 | 0.06 | 1,773.25 |
| Oct 2026 | 21,570 | 8.6 | 2.54 | 0.06 | 1,827.74 |
| Oct 2026 | 21,465 | 8.6 | 2.60 | 0.06 | 1,871.68 |
| Oct 2026 | 21,600 | 8.6 | 2.52 | 0.06 | 1,810.95 |
| Oct 2026 | 21,445 | 8.9 | 2.61 | 0.06 | 1,877.36 |
| Oct 2026 | 21,299 | 9.2 | 2.69 | 0.06 | 1,938.05 |
| Oct 2026 | 21,356 | 9.1 | 2.66 | 0.06 | 1,909.61 |
| Oct 2026 | 21,328 | 9.1 | 2.68 | 0.06 | 1,917.08 |
Acadia Pharmaceuticals Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 307,959,000.0 | 268,062,000.0 | 283,989,000.0 | 278,633,000.0 |
| Net Profit | 31,500,000.0 | 3,637,000.0 | 273,568,000.0 | 71,779,000.0 |
| EPS | 0.2 | 0.0 | 1.6 | 0.4 |
Acadia Pharmaceuticals Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 1,071,505,000.0 | 957,797,000.0 | 726,437,000.0 | 517,235,000.0 | — |
| Net Profit | 391,000,000.0 | 226,451,000.0 | -61,286,000.0 | -215,975,000.0 | — |
| EPS | 2.3 | 1.4 | -0.4 | -1.3 | — |
Acadia Pharmaceuticals Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,564,195,000.0 | 1,187,756,000.0 | 748,956,000.0 | 587,812,000.0 | — |
| Total Liabilities | 336,805,000.0 | 454,963,000.0 | 317,201,000.0 | 187,399,000.0 | — |
| Total Equity | 1,227,390,000.0 | 732,793,000.0 | 431,755,000.0 | 400,413,000.0 | — |
Owes vs Owns
Acadia Pharmaceuticals Inc. owed $0.25 for every $1 it owned in Jun 2026, down from $0.32 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.25× | 0.22× | 0.38× | 0.42× | 0.32× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Acadia Pharmaceuticals Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 52.4%Receivables 9.5%Inventory 2.2%Fixed assets (tangible) 3.5%Intangible assets 7.0%Other assets 25.4%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 2.6%Payables 0.7%Other liabilities 17.5%Shareholders' equity 78.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 819.7 | 756.0 | 438.9 | 416.8 |
| Receivables | 148.2 | 104.7 | 102.3 | 63.1 |
| Inventory | 34.7 | 21.9 | 35.8 | 6.6 |
| Fixed assets (tangible) | 54.9 | 50.8 | 56.5 | 61.6 |
| Intangible assets | 108.9 | 119.8 | 65.5 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 397.9 | 134.6 | 50.0 | 39.7 |
| Liabilities & equity | ||||
| Short-term debt | 11.6 | 10.0 | 9.4 | 9.3 |
| Long-term debt | 40.6 | 42.0 | 47.8 | 52.7 |
| Payables | 10.9 | 16.2 | 17.5 | 12.7 |
| Other liabilities | 273.7 | 386.8 | 242.5 | 112.7 |
| Shareholders' equity | 1,227.4 | 732.8 | 431.8 | 400.4 |
| Net tangible assets | 1,118.5 | 613.0 | 366.3 | 400.4 |
Acadia Pharmaceuticals Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 109,836,000.0 | 157,719,000.0 | 16,702,000.0 | -114,035,000.0 | — |
| Investing Activities | -302,564,000.0 | -30,538,000.0 | 31,998,000.0 | 73,241,000.0 | — |
| Financing Activities | 49,883,000.0 | 6,845,000.0 | 25,129,000.0 | 8,199,000.0 | — |